Iridex Corp. (NSDQ:IRIX) nabbed approval from the Japan Ministry of Health, Labor and Welfare for its extended family of EndoProbe laser delivery devices.
The Mountain View, Calif.-based ophthalmic device maker isn’t letting the grass grow under its feet, announcing the concomitant launch of the devices in Japan as well.
The newly approved surgical tools are an intraocular laser delivery device used during vitreo-retinal surgery for the treatment of disorders including diabetic retinopathy, retinal detachments and vitreous hemorrhage.
The EndoProbe product family includes single-use devices with standard, shaped and specialized designs and may be used with currently installed Iridex ophthalmic laser systems, according to the company.
